Events | 2019.09.19
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
BASEL, Switzerland, Sept. 19, 2019 /PRNewswire/ -- New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate major milestone gain Updated results from global STR1VE study demonstrate that Zolgensma®...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]muscular-atrophy-sma-type-1-30
Follow us on
📊 Most Viewed News
- • The complete guide to making your product international - The Nex... (15,542)
- • Colaboração 2.0: Breaking Down the Language Barrier - Business ... (12,035)
- • A Start-Up Bets on Human Translators Over Machines - New York Tim... (11,530)
- • Immigrants 'should learn English' - Politics.co.uk (11,211)
- • How OpenStack gets translated - opensource.com (11,048)
- • easyJet Chooses TransPerfect for Pan-European Translation - Busin... (10,937)
- • Para-Plus Translations Honored by Philadelphia Business Journal .... (10,367)
- • Google Adds Customized Translations for Website Owners - PC Magaz... (10,257)